Diabetes Care 39 (4), 617624
There are currently four popular GLP-1 agonists approved by the FDA (two FDA-approved agonists, lixisenatide and exenatide, have been discontinued in recent years)
The key is to understand that every persons body responds differently to these medications
Where this is headed GLP-1s arent going away
Sheer and colleagues reviewed electronic health record data from 26,408 adults treated in the OneFlorida+ network from 2014 to 2024, covering 14 healthcare organizations across Florida, Georgia, and Alabama
Furthermore, some were these drugs were associated with potential undesirable effects, such as the risk of heart failure or fractures (complications that are especially prevalent in patients with CKD), this is the case of thiazolidinediones, and the use of sulfonylureas and insulin are associated with weight gain or the risk of hypoglycemia